Diabetes

Dr Diana Isaacs reviews the significance of Eversense’s recent approval for a 180-day indication and the potential role of Dexcom G7 in the diabetes treatment landscape.

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, comments on the accuracy and selection of CGMs in treating diabetes and shares insight on the evolution of CGM systems over the past year.

SuperWIN trial findings suggest the future of successful health care depends on harnessing familiar, community- based resources to maintain health and deliver care.

Wade Brosius, DO, Shelton Hager, MD, and Steven Peskin, MD, answer questions relating to diabetic retinopathy screening devices and highlight novel technologies utilized in this space.

A panel of experts in the management of diabetes answer questions relating to the importance of early screening and detection of diabetic retinopathy and provide practice pearls for how to facilitate in-office screenings.

Allen Dobson, Jr., MD, FAAFP, reviews the case of a 49-year-old woman with type 2 diabetes and the panel comments on their approaches to continued care and disease prevention.

Wade Brosius, DO, and Steven Peskin, MD, review the cost of care and reimbursement schemes available to practitioners completing diabetic retinopathy screenings.

Key opinion leaders in diabetes management provide insight on recognizing and addressing barriers to care and screening for diabetic retinopathy.

Allen Dobson, Jr., MD, FAAFP, reviews the case of a 67-year-old man with type 2 diabetes and the panel discusses initial diagnosis and management.

Key opinion leaders in diabetes management comment on the practical considerations of screening in clinical practices and note the importance of creating a replicable workflow for busy practices.

An expert in the management of diabetes provides insight into common challenges leading to low rates of diabetic retinopathy screening in primary care settings, highlighting the need to increase access to care.

Wade Brosius, DO, and Steven Peskin, MD, discuss the clinical and economic burden of diabetic retinopathy, highlighting the impact on patients’ quality of life and the health care system.

Allen Dobson, Jr., MD, FAAFP; Wade Brosius, DO; and Shelton Hager, MD, provide an overview of diabetic retinopathy and discuss risk factors leading to its pathogenesis.

An expert in diabetes management discusses the role of CGMs in treating diabetes during the COVID-19 pandemic and the benefits of using CGM in telemedicine.

Dr Diana Isaacs provides insight on patient factors to consider for CGM use in diabetes treatment.

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, reviews the advantages of CGMs in treating type 1 and type 2 diabetes and how CGMs can improve glycemic control and quality of life in patients.

In patients with type 2 diabetes and chronic kidney disease with and without history of CVD, finerenone was associated with improved CV and kidney outcomes.

DiabetesWise Pro, created at Stanford University, provides an unbranded, unbiased guide to matching diabetes technology to patient needs, access, and lifestyle.

Initiating diabetes technology of any kind is a big step for patients, but also for a lot of primary care clinicians. If you have concerns, these myths and facts are for you.

ACC 2022: Updated findings further highlight benefit of sotagliflozin treatment in patients with T2D and CKD, regardless of cardiovascular disease presence.

The higher dose of the GLP-1 analogue allows more flexibility for patients with T2D needing to intensify treatment, says manufacturer Novo Nordisk.

Persons with type 2 diabetes who either gained or lost 5% of baseline bodyweight were found to be at higher risk for heart failure, MI, and all-cause death.

The phase 3 EMPA-KIDNEY clinical trial had just met prespecified criteria for positive efficacy when the study's Independent Data Monitoring Committee recommended the early halt.

Moderate consumption of alcohol with food was significantly associated with a 14% lower risk of type 2 diabetes in a preliminary analysis.

Glycemic variability and low time in range were associated with retinopathy, nephropathy, neuropathy, and CVD in a cohort of more than 20 000 persons, most with T2D.

The landmark approval for the SGLT-2 inhibitor will open access to treatment for the ~ 3 million adults with heart failure with preserved ejection fraction.

t:slim X2 insulin pump users can now program or cancel bolus dosing with the secure t:connect mobile app already on their phones, says Tandem Diabetes Care.

US patients at high CV risk do not receive adequate evidence-based pharmacotherapy, according to large multisite cohort analysis.

Researchers in Taiwan found NOACs were associated with lower hazards of diabetes complications. and death than warfarin in persons with AF and DM.

The 2022 DSMES National Standards update focuses on reducing administrative burden on educators and improving person-centered care for patients.